Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a......
(read more)September 17 - Hedge Funds, News - Comments
The Chinese calendar says 2013 is the year of the snake, but the market says it’s the year of biotech. Major biotechnology ETFs and indices have......
(read more)September 17 - News - Comments
There are plenty of biotech companies that put all of their eggs in one basket these days. For speculative traders, these stocks can lead to exciting......
(read more)September 16 - News - Comments
The last several months have been remarkably exciting in the biotech space. For patients, it appears that groundbreaking treatments for hepatitis C and......
(read more)September 11 - News - Comments
A year ago, Best Buy Co., Inc. (NYSE:BBY) founder Richard Schulze wanted to team up with private equity investors to buy enough shares to take the consumer......
(read more)August 27 - News - Comments
What’s better than momentum? Mo’ momentum. Let’s take a closer look at five of this past week’s biggest scorchers. Company Aug......
(read more)August 19 - News - Comments
In a companion article a few days ago, I predicted that MannKind Corporation (NASDAQ:MNKD)‘s extended phase 3 program for its inhaled insulin,......
(read more)August 12 - News - Comments
Babe Ruth wasn’t afraid to swing for the fences. That’s how he became Major League Baseball’s home run king for decades. If you’......
(read more)July 15 - News - Comments
There’s never a shortage of losers in the stock market. Let’s take a closer look at five of this past week’s biggest sinkers. Company......
(read more)July 15 - News - Comments
For the last few weeks, there has been a heated debate regarding the success or lack thereof from biotechnology company Amarin Corporation plc (ADR) (......
(read more)July 10 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a......
(read more)July 5 - Hedge Funds - Comments
Just as we examine companies each week that may be rising past their fair value, we can also find companies potentially trading at bargain prices. While......
(read more)June 27 - News - Comments
Mark your calendars Amarin Corporation plc (ADR) (NASDAQ:AMRN) investors. The biotech’s fish oil, Vascepa, will get its day in front of a Food and......
(read more)June 20 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a......
(read more)June 20 - Hedge Funds - Comments
Amarin Corporation plc (ADR) (NASDAQ:AMRN) has recently launched its primary product candidate Vascepa into the market. The drug is an omega-3 fatty acid......
(read more)June 10 - News - Comments
AstraZeneca plc (ADR) (NYSE:AZN) announced the acquisition of Omthera Pharmaceuticals Inc (NASDAQ:OMTH), a company that went public just last month (April......
(read more)June 10 - News - Comments
GlaxoSmithKline plc (ADR) (NYSE:GSK)‘s diabetes drug Avandia causes heart issues. Or maybe it doesn’t. Either way, regulators figured the......
(read more)June 10 - News - Comments
It’s not just about offering a better drug, but it’s also about launching it at the right time in the market. This is what I learned while studying......
(read more)April 28 - News - Comments
As an investor, it pays to follow the cash. If you figure out how a company moves its money, you might eventually find some of that cash flowing into......
(read more)March 27 - News - Comments
Some stocks take a pounding, but there’s usually what they call a dead-cat bounce. Even if a stock’s inevitable path is to head lower, there......
(read more)March 25 - News - Comments
Sequester or no sequester, the folks at the Food and Drug Administration look to be quite busy in 2013. Their schedules are full with plenty of important......
(read more)March 25 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a......
(read more)March 20 - Hedge Funds - Comments
Last year, a number of drugs received FDA approval. The drug authority has rolled out one approval after another, maybe to compensate for the patent cliff......
(read more)March 14 - News - Comments
It’s not just Catholics watching a certain Vatican City smokestack. As cardinals gather to elect a new pope, the conclave uses a smokestack to communicate......
(read more)March 14 - News - Comments
Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to discuss Amarin Corporation plc (ADR) (NASDAQ:AMRN) , a biotech......
(read more)March 6 - News - Comments
The last year has been a stellar one for the biotechnology industry. The industry has easily outperformed the market, with all of its indices, including......
(read more)February 26 - News - Comments
All throughout Wall Street we keep hearing about Amarin Corporation plc (ADR) (NASDAQ:AMRN) being bought out by some type of Big Pharma company in the......
(read more)February 22 - News - Comments
Baltimore won. Beyonce rocked. But some health-care stocks didn’t have such great experiences. Here are three of the most horrendous performers......
(read more)February 9 - News - Comments
Every quarter, many money managers have to disclose what they’ve bought and sold, via “13F” filings. Their latest moves can shine a......
(read more)February 6 - Hedge Funds - Comments
After several days of focusing on the economy, investors have had their attention pulled squarely back on earnings season, and some of the news hasn&#......
(read more)January 21 - News - Comments
